Leptin antagonism inhibits prostate cancer xenograft growth and progression
Our study by Dr Philp et al reveals the world-first preclinical evidence that demonstrates marked efficacy of targeted leptin-signalling blockade, using Allo-aca, a potent, specific, and safe LEPR peptide antagonist. This highlights LEPR blockade in combination with androgen axis inhibition as a promising new therapeutic strategy vital in advanced PCa treatment.
